An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers presented new results at the EASD 2026 meeting showing that people who switched from injectable GLP-1 drugs (like Ozempic/Wegovy) to an oral form of semaglutide continued to lose weight. In short: taking the pill version of semaglutide after stopping an injectable GLP‑1 still led to further weight reduction in the people studied. Semaglutide is the active ingredient in several popular injectable drugs used for diabetes and weight loss. It’s a lab-made copy of a natural gut hormone that tells your brain you’re full, slows stomach emptying, and helps control blood sugar. Injectable semaglutide is well known; oral semaglutide is a pill form of the same drug designed so it can be absorbed when swallowed. The new data looked at people who were already on injectable GLP‑1 medicines and then switched to oral semaglutide. The report says these people lost additional weight after the switch. The summary doesn’t spell out how many people were in the study, how long they were followed, or exactly how much weight they lost, so we can’t say how big or reliable the effect is. It’s also unclear whether the participants had diabetes, obesity without diabetes, or a mix. Those details matter for judging who the findings apply to. Why this might matter is practical. Many patients dislike injections or have trouble with them. If a pill version can keep delivering benefits like weight loss, more people might prefer it. A pill is easier to take for day-to-day life and could expand options for people managing weight or blood sugar. Clinicians might consider oral semaglutide as an alternative for patients who want to stop injections but still keep the drug’s effects. There are important caveats. Pills and injections can differ in how consistently the body absorbs the drug, so effects may vary between people. Side effects known for semaglutide include nausea, stomach upset, and in rare cases more serious issues like pancreatitis or gallbladder problems. The report doesn’t offer long-term safety data for switching formulations. Also, without full study details, we don’t know if the switch is safe or effective for everyone, such as people with certain medical conditions or those taking other medications. Bottom line: Early results suggest switching from injectable GLP‑1s to oral semaglutide can still lead to weight loss for some people, but we need the full study details and longer-term data to know how well and how safely this works for different patients.
Source: Clinical Trials Arena